1
|
Roth M, King L, St Cyr K, Mohsin U, Balderson K, Rhind S, Goldman A, Richardson D. Evaluating the prospective utility of pharmacogenetics reporting among Canadian Armed Forces personnel receiving pharmacotherapy: a preliminary assessment towards precision psychiatric care. BMJ Mil Health 2023:e002447. [PMID: 37657847 DOI: 10.1136/military-2023-002447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Accepted: 07/18/2023] [Indexed: 09/03/2023]
Abstract
Pharmacological interventions for treating posttraumatic stress disorder in Canadian Armed Forces (CAF) members and Veterans often achieve modest results. The field of pharmacogenetics, or the study of how genes influence an individual's response to different medications, offers insight into how prior knowledge of gene-drug interactions may potentially improve the trial-and-error process of drug selection in pharmacotherapy, thereby improving treatment effects and remission rates. Given the relative recency of pharmacogenetics testing and sparse research in military samples, we used pharmacogenetics testing in a small pilot group (n=23) of CAF members and Veterans who were already engaged in pharmacotherapy for a service-related mental health condition to better understand the associated opportunities and challenges of pharmacogenetics testing in this population. Our preliminary evaluation involved: (1) reporting the prevalence of pharmacogenetics testing 'bin' status according to participants' reports ('green', 'yellow' or 'red'; intending to signal 'go', 'caution' or 'stop', regarding the potential for gene-drug interactions); (2) calculating the percentage of currently prescribed psychotropic medications that were assessed and included in the reports; (3) evaluating whether prescribers used pharmacogenetics testing information according to clinical notes and (4) collecting informal feedback from participating psychiatrists. While pharmacogenetics testing appeared to provide valuable information for a number of clients, a major limitation was the number of commonly prescribed medications not included in the reports.
Collapse
Affiliation(s)
- Maya Roth
- Operational Stress Injury Clinic-Greater Toronto Site, St. Joseph's Health Care, London, Toronto, Ontario, Canada
- MacDonald Franklin Operational Stress Injury Research Centre, London, Ontario, Canada
| | - L King
- Operational Stress Injury Clinic - Parkwood Main Site, SJHC, London, Ontario, Canada
| | - K St Cyr
- MacDonald Franklin Operational Stress Injury Research Centre, London, Ontario, Canada
- University of Toronto Dalla Lana School of Public Health, Toronto, Ontario, Canada
| | - U Mohsin
- University of Toronto, Toronto, Ontario, Canada
| | - K Balderson
- Operational Stress Injury Clinic - Parkwood Main Site, SJHC, London, Ontario, Canada
| | - S Rhind
- Defence Research and Development Canada, Toronto, Ontario, Canada
| | - A Goldman
- DNA Labs Canada Inc, Toronto, Ontario, Canada
| | - D Richardson
- MacDonald Franklin Operational Stress Injury Research Centre, London, Ontario, Canada
- Operational Stress Injury Clinic - Parkwood Main Site, SJHC, London, Ontario, Canada
| |
Collapse
|
2
|
Esemen Y, Mostofi A, Richardson D, Pereira EAC. Are we meeting the standards set for informed consent in spinal surgery? Ann R Coll Surg Engl 2023; 105:372-377. [PMID: 35904335 PMCID: PMC10066640 DOI: 10.1308/rcsann.2022.0049] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/30/2022] [Indexed: 11/22/2022] Open
Abstract
INTRODUCTION Informed consent empowers patients to exercise their autonomy and actively participate in their medical care. Guidance published by the British Association of Spine Surgeons (BASS) lists three components of consent: provision of information booklets, patient-centred dialogue and completion of appropriate consent forms. The aim of the study was to review the quality of the spinal surgery consent process against the BASS guidance in a single tertiary neurosurgery centre in London. METHODS Retrospective review of clinic letters and consent forms was performed for 100 consecutive cases of elective, non-instrumented spinal decompression surgeries performed in 2019. Documentation was graded for inclusion of the intended benefit (improvement of pain/prevention of neurological deterioration), alternative management options (including no treatment), surgical options and risks (infection, bleeding, paralysis, sphincter disturbances, dural tear and recurrence). Provision of supplementary information booklets was recorded. Two-tailed Fisher exact test was used to calculate statistical significance where appropriate. RESULTS Documentation of indications and risks of elective spinal surgery, specifically risk of recurrence (62%) and sphincter disturbance (85%), was suboptimal on the consent forms. Documentation of these risks was also poor in clinic letters (<50%). Alternative treatment options were explained in less than half of the clinic letters, and there was no documentation of information booklet provision prior to elective surgeries. CONCLUSION Lack of informed consent plays a major role in medical malpractice claims in spinal surgery. Poor documentation puts the surgeon in a liable position. BASS guidance could be implemented to create a more standardised process of consent in spinal surgery.
Collapse
|
3
|
Messing S, Tcymbal A, Abu-Omar K, Richardson D, Gelius P. Methods of policy monitoring in physical activity promotion: a systematic review across different levels of government. Eur J Public Health 2022. [PMCID: PMC9594761 DOI: 10.1093/eurpub/ckac129.269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Background Even though the importance of policy monitoring in public health has increased in the last decades, there is still a lack of understanding what different approaches of policy monitoring exist and which methodology they employ. In order to address this research gap, this review attempts to provide a comprehensive overview about the methods of policy monitoring in the field of physical activity promotion. Methods A systematic search was conducted in five scientific databases, using the terms “physical activity”, “policy” and “monitoring” and their variations. In total, 12.963 studies were identified and, after the elimination of duplicates, screened independently by two reviewers. During full text analysis, information on the methods applied for policy monitoring was extracted and studies were categorized based on their key characteristics (monitoring tool, policy level, and setting). Results The search yielded in a total of 112 studies that were structured into seven categories: Report Cards on Physical Activity for Children and Youth, HEPA Monitoring Framework, HEPA Policy Audit Tool, national policies, subnational policies, school setting, and childcare setting. Across all categories, policy monitoring focused mainly on national level policies in a single country. Differences were identified with regards to the level of government involvement which allowed to differentiate between research-driven approaches (little or no government involvement), government-driven approaches (led by governments), and co-production approaches (strong collaboration between researchers and governments). Conclusions Research-driven, government-driven and co-production approaches have different strengths and weaknesses with regards to the monitoring of policies. Awareness needs to be raised regarding the implications of these approaches, and more research is needed to analyse the impact of policy monitoring on policy-making in public health.
Collapse
Affiliation(s)
- S Messing
- Department of Sport Science and Sport, Friedrich-Alexander-Universität Erlangen-Nürn , Erlangen, Germany
| | - A Tcymbal
- Department of Sport Science and Sport, Friedrich-Alexander-Universität Erlangen-Nürn , Erlangen, Germany
| | - K Abu-Omar
- Department of Sport Science and Sport, Friedrich-Alexander-Universität Erlangen-Nürn , Erlangen, Germany
| | - D Richardson
- Department of Sport Science and Sport, Friedrich-Alexander-Universität Erlangen-Nürn , Erlangen, Germany
| | - P Gelius
- Department of Sport Science and Sport, Friedrich-Alexander-Universität Erlangen-Nürn , Erlangen, Germany
| |
Collapse
|
4
|
Lu M, Shaw P, Richardson D, Hamilton E, Bernardo P, Bradshaw C, Tolcher A, Mosher R. Archival vs fresh tumor samples for assessing the gene expression of NaPi2b and immune-related genes in the Phase 1b study of Upifitamab Rilsodotin (UpRi) in platinum-resistant ovarian cancer. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01033-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
5
|
Marroney N, Richardson D, Cole E, Hammond J. Devising and implementing an education strategy for therapists working within the major trauma network. Physiotherapy 2021. [DOI: 10.1016/j.physio.2021.10.212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
6
|
Watson E, Sanapala C, Klepin H, Mohile S, Wittink M, Norton S, Richardson D, Dale W, Magnuson A, Mendler J, Liesveld J, Huselton E, Leblanc T, El-Jawahri A, Wong M, Yang S, Loh K. Developing and adapting a patient-centered communication tool (UR-GOAL) for older patients with acute myeloid leukemia (AML) and their oncologist. J Geriatr Oncol 2021. [DOI: 10.1016/s1879-4068(21)00358-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Gutiérrez-García G, Martínez C, Boumendil A, Finel H, Malladi R, Afanasyev B, Tsoulkani A, Wilson KMO, Bloor A, Nikoloudis M, Richardson D, López-Corral L, Castagna L, Cornelissen J, Giltat A, Collin M, Fanin R, Bonifazi F, Robinson S, Montoto S, Peggs KS, Sureda A. Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT. Br J Haematol 2021; 196:1018-1030. [PMID: 34750806 DOI: 10.1111/bjh.17939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Revised: 10/19/2021] [Accepted: 10/20/2021] [Indexed: 11/30/2022]
Abstract
We analysed long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation (allo-HSCT) as a first transplant for high-risk Hodgkin lymphoma (HL). One hundred and ninety patients were included in this study, 63% of them had previously received brentuximab vedotin and/or checkpoint inhibitors. Seventy patients (37%) received an unrelated donor allo-HSCT, 99 (51%) had myeloablative conditioning (MAC) and 60% had in vivo T-cell/depleted grafts (TCD). The 100-day cumulative incidence (CI) of grade II-IV acute graft-versus-host disease (GVHD) was 25% and the 3-year CI of chronic GVHD was 38%. The 3-year CI of non-relapse mortality (NRM) and relapse rate were 21% and 38% respectively. After a median follow-up of 58 months, 3-year overall survival (OS) and progression-free survival (PFS) were 58% and 41% respectively. Multivariate analysis showed that, in comparison to reduced-intensity conditioning regimens with or without TCD, MAC using TCD had similar NRM and a lower risk of relapse leading to significantly better OS and PFS. MAC without TCD was associated with higher NRM and worse survival outcomes. These results suggest that in patients with high-risk HL and candidates of allo-HSCT, a MAC strategy with TCD might be the best option.
Collapse
Affiliation(s)
- G Gutiérrez-García
- Department of Haematology, Bone Marrow Transplantation Unit, Hospital Clinic of Barcelona, University of Barcelona, Institut de Recerca Biomèdica August Pi i Sunyer, Barcelona, Spain
| | - C Martínez
- Department of Haematology, Bone Marrow Transplantation Unit, Hospital Clinic of Barcelona, University of Barcelona, Institut de Recerca Biomèdica August Pi i Sunyer, Barcelona, Spain
| | | | - H Finel
- Lymphoma Working Party, EBMT, Paris, France
| | - R Malladi
- School of Cancer Sciences, University of Birmingham, Centre for Clinical Haematology, Queen Elizabeth NHS Foundation Trust, Birmingham, UK
| | - B Afanasyev
- State Medical Pavlov University, St. Petersburg, Russia
| | | | | | - A Bloor
- Haematology and Transplant Unit, Christie Hospital NHS Foundation Trust and University of Manchester, Manchester, UK
| | - M Nikoloudis
- Haematology Department Heart of England NHS Trust, Birmingham, UK
| | - D Richardson
- Department of Haematology, Southampton General Hospital, Southampton, UK
| | | | - L Castagna
- Department of Haematology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
| | - J Cornelissen
- Erasmus MC Cancer Institute University Medical Centre Rotterdam Department of Haematology, Rotterdam, Netherlands
| | - A Giltat
- Department of Haematology, Medical University Hospital, Angers, France
| | | | - R Fanin
- Department of Haematology and Cellular Therapy 'Carlo Melzi', S. Maria della Misericordia University Hospital, DAME, University of Udine, Udine, Italy
| | - F Bonifazi
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Bologna, Italy
| | - S Robinson
- Department of Haematology and Oncology, Bristol University Hospital, Bristol, UK
| | - S Montoto
- St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - K S Peggs
- Department of Haematology, University College London Cancer Institute, London, UK
| | - A Sureda
- Clinical Department of Haematology, Institut Català d'Oncologia-Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain
| |
Collapse
|
8
|
Bhate R, Colman J, Fowler T, Hayley J, Kallam N, Mak TLA, Matthews F, Norton E, Richardson D. 1536 Neuroanatomy, Not Just for Budding Neurosurgeons. Motivations for Participating in An Extra-Curricular Neuroanatomy Course for Undergraduates. Br J Surg 2021. [DOI: 10.1093/bjs/znab259.909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Introduction
Extra-curricular activities form an important part of undergraduate education as they give students the opportunity to explore subjects of interest. There is significant demand within the undergraduate population for further teaching in neuro-related specialities. The aim of this online twelve-week course was to provide neuroanatomy teaching in greater breadth and detail than possible in the undergraduate curriculum. We sought to gauge motivations for involvement.
Method
Delegates (n = 166) from six UK universities were asked to complete a short questionnaire examining motivations and future career plans prior to the course beginning, only those who consented were involved further in the analysis (n = 98).
Results
Motivations for involvement were predominantly to develop a greater understanding of neuroanatomy (63.3%), to support career plans (13.3%) or to support preparation for an examination or competition (8.2%). The majority (56.1%) had no particular speciality in mind. For those who did, a range of specialities including neurosurgery (24.5%), neurology (8.2%) was given.
Conclusions
There is clear interest within the undergraduate population for more specialised extra-curricular activities in addition to conventional experiences such as conferences. Online courses run over multiple weeks provide further scope for depth and exploration of subjects in further detail. In this course, the majority of delegates did not have a particular speciality in mind, demonstrating neuroanatomy to be a popular subject regardless of potential career plans. For students looking to pursue a career in neuro-related specialities, courses are perceived as important opportunities to support future career development.
Collapse
Affiliation(s)
- R Bhate
- St. George's, University of London, London, United Kingdom
| | - J Colman
- University College London, London, United Kingdom
| | - T Fowler
- King George Hospital, Ilford, United Kingdom
| | - J Hayley
- St. George's, University of London, London, United Kingdom
| | - N Kallam
- Royal Free London NHS Foundation Trust, London, United Kingdom
| | - T L A Mak
- St. George's, University of London, London, United Kingdom
| | - F Matthews
- St. George's, University of London, London, United Kingdom
| | - E Norton
- University of Cambridge, Cambridge, United Kingdom
| | - D Richardson
- St. George's, University of London, London, United Kingdom
| |
Collapse
|
9
|
Bhate R, Colman J, Fowler T, Hayley J, Kallam N, Mak TLA, Matthews F, Norton E, Richardson D. 1520 Decoding Neurophobia – Insights from an Undergraduate Neuroanatomy Course. Br J Surg 2021. [DOI: 10.1093/bjs/znab259.908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Introduction
Neurophobia is a common multifaceted issue amongst students studying medical sciences at an undergraduate level associated with difficulty in understanding neuroscience topics and ongoing negative perceptions of clinical neurosciences. We sought to examine whether neurophobia was present even amongst students who participated in an extracurricular neuroanatomy teaching course.
Method
Prior to the beginning of a twelve-week online neuroanatomy course, delegates were asked to complete a short questionnaire examining perceptions of neurophobia and specialities of interest. This was repeated after the course. This course was open to all undergraduate students in the UK and covered material beyond the remits of the undergraduate curriculum.
Results
From the 166 signups, 98 students completed the pre-course questionnaire. As expected, the majority of students (n = 83) taking part did not identify as neurophobic, describing the subject area as ‘interesting’, ‘enjoyable’ and ‘challenging’. Students who identified as neurophobic described neuroanatomy as ‘complex’ or ‘overwhelming’. Some students (n = 12) continued to describe themselves as neurophobic at the end of the course, despite this 7 of those students continue to consider a future career in a neuro-related speciality.
Conclusions
The fact that students with Neurophobia attended this extra-curricular course speaks volumes of how perception and self-motivation of a student are important for learning a subject. All students who participated in this course recognised the complexity and interesting nature of neuroanatomy. This experience highlights the challenge of medical educators to provide teaching experiences that are stimulating and enjoyable, but not overwhelming.
Collapse
Affiliation(s)
- R Bhate
- St. George's, University of London, London, United Kingdom
| | - J Colman
- University College London, London, United Kingdom
| | - T Fowler
- King George Hospital, Ilford, United Kingdom
| | - J Hayley
- St. George's, University of London, London, United Kingdom
| | - N Kallam
- Royal Free London NHS Foundation Trust, London, United Kingdom
| | - T L A Mak
- St. George's, University of London, London, United Kingdom
| | - F Matthews
- St. George's, University of London, London, United Kingdom
| | - E Norton
- University of Cambridge, Cambridge, United Kingdom
| | - D Richardson
- St. George's, University of London, London, United Kingdom
| |
Collapse
|
10
|
Richardson D, Samarasekara K, Ringshall M, Parashar K, Nichols K, Devlin J, Buss Z, Pickering A, Fitzpatrick C, Williams D. The characteristics of men who have sex with men who present as sexual contacts of gonorrhoea from a clinic-based population. J Eur Acad Dermatol Venereol 2021; 35:e926-e928. [PMID: 34370354 DOI: 10.1111/jdv.17589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2021] [Accepted: 07/29/2021] [Indexed: 11/30/2022]
Affiliation(s)
- D Richardson
- University Hospitals, Sussex, Brighton, UK.,Brighton & Sussex Medical School, Brighton, UK
| | | | | | - K Parashar
- University Hospitals, Sussex, Brighton, UK
| | - K Nichols
- University Hospitals, Sussex, Brighton, UK
| | | | - Z Buss
- University Hospitals, Sussex, Brighton, UK
| | | | | | - D Williams
- University Hospitals, Sussex, Brighton, UK
| |
Collapse
|
11
|
Richardson D, Trotman D, Devlin J, Buss Z, Fortescue-Talwar R, Fitzpatrick C, Williams D. Gonorrhoea proctitis in men who have sex with men: The importance of performing culture specimens for antimicrobial resistance surveillance. J Eur Acad Dermatol Venereol 2021; 35:e873-e875. [PMID: 34242436 DOI: 10.1111/jdv.17503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2021] [Revised: 06/08/2021] [Accepted: 06/25/2021] [Indexed: 11/28/2022]
Affiliation(s)
- D Richardson
- University Hospitals Sussex NHS Foundation NHS Trust, Sexual Health & HIV Medicine, Brighton, UK.,Brighton & Sussex Medical School, Brighton, UK
| | - D Trotman
- University Hospitals Sussex NHS Foundation NHS Trust, Sexual Health & HIV Medicine, Brighton, UK
| | - J Devlin
- University Hospitals Sussex NHS Foundation NHS Trust, Sexual Health & HIV Medicine, Brighton, UK
| | - Z Buss
- University Hospitals Sussex NHS Foundation NHS Trust, Sexual Health & HIV Medicine, Brighton, UK
| | - R Fortescue-Talwar
- University Hospitals Sussex NHS Foundation NHS Trust, Sexual Health & HIV Medicine, Brighton, UK
| | - C Fitzpatrick
- University Hospitals Sussex NHS Foundation NHS Trust, Sexual Health & HIV Medicine, Brighton, UK
| | - D Williams
- University Hospitals Sussex NHS Foundation NHS Trust, Sexual Health & HIV Medicine, Brighton, UK
| |
Collapse
|
12
|
Richardson D, Greenway F, Mostofi A, Pereira E. 307 Improving Compliance with Standard of Care Guidelines for Suspected Cauda Equina Syndrome Across A District General Hospital Network. Br J Surg 2021. [DOI: 10.1093/bjs/znab134.400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Introduction
Cauda equina syndrome (CES) is a spinal emergency that cannot be reliably detected through clinical examination alone and as a result requires prompt MR imaging to provide a diagnosis. This audit examined compliance to standard of care following service improvements in line with the updated SBNS/BASS national guidelines for CES.
Method
A retrospective analysis of 200 patients referred to neurosurgery for suspected CES: 100 pre- and 100 post-service improvement SBNS guideline implementation.
The online neurosurgical database was reviewed, cases assessed for completeness of referral information (including appropriate exam and pre-referral MRI) with patient demographics, referring hospital and outcome also recorded.
Results
Prior to the SBNS guidelines only 19 patients received MRI prior to referral, 70% of all referrals were incomplete or contained erroneous clinical information. Post-service improvements there was a 68% increase of pre-referral MRI (32 cases), and an improvement in quality of clinical information with only 19% of referrals providing insufficient or unreliable information.
Conclusions
Through relatively simple changes to local policy, patient care flow and education of emergency department clinicians we have significantly improved pre-referral MRI rates as well as overall referral quality across the whole DGH network.
Collapse
Affiliation(s)
- D Richardson
- St George's, University of London, London, United Kingdom
| | - F Greenway
- Department of Neurosurgery, St George's Hospital, London, United Kingdom
| | - A Mostofi
- Department of Neurosurgery, St George's Hospital, London, United Kingdom
| | - E Pereira
- Department of Neurosurgery, St George's Hospital, London, United Kingdom
| |
Collapse
|
13
|
Richardson D, Nichols K, Pickering A, Devlin J, Buss Z, Fitzpatrick C, Cresswell F. Transitioning from HIV post-exposure prophylaxis to pre-exposure prophylaxis in men who have sex with men. HIV Med 2021; 22:780-781. [PMID: 33930241 DOI: 10.1111/hiv.13112] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/25/2021] [Indexed: 11/26/2022]
Affiliation(s)
- D Richardson
- Brighton & Sussex University Hospitals NHS Trust, Brighton, UK.,Brighton & Sussex Medical School, Brighton, UK
| | - K Nichols
- Brighton & Sussex University Hospitals NHS Trust, Brighton, UK
| | - A Pickering
- Brighton & Sussex University Hospitals NHS Trust, Brighton, UK
| | - J Devlin
- Brighton & Sussex University Hospitals NHS Trust, Brighton, UK
| | - Z Buss
- Brighton & Sussex University Hospitals NHS Trust, Brighton, UK
| | - C Fitzpatrick
- Brighton & Sussex University Hospitals NHS Trust, Brighton, UK
| | - F Cresswell
- Brighton & Sussex University Hospitals NHS Trust, Brighton, UK.,London School of Tropical Medicine and Hygiene, London, UK
| |
Collapse
|
14
|
Lowe R, Ferrari M, Nasim-Mohi M, Jackson A, Beecham R, Veighey K, Cusack R, Richardson D, Grocott M, Levett D, Dushianthan A. Clinical characteristics and outcome of critically ill COVID-19 patients with acute kidney injury: a single centre cohort study. BMC Nephrol 2021; 22:92. [PMID: 33722189 PMCID: PMC7957445 DOI: 10.1186/s12882-021-02296-z] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Accepted: 03/08/2021] [Indexed: 01/09/2023] Open
Abstract
BACKGROUND Acute kidney injury (AKI) is a common manifestation among patients critically ill with SARS-CoV-2 infection (Coronavirus 2019) and is associated with significant morbidity and mortality. The pathophysiology of renal failure in this context is not fully understood, but likely to be multifactorial. The intensive care unit outcomes of patients following COVID-19 acute critical illness with associated AKI have not been fully explored. We conducted a cohort study to investigate the risk factors for acute kidney injury in patients admitted to and intensive care unit with COVID-19, its incidence and associated outcomes. METHODS We reviewed the medical records of all patients admitted to our adult intensive care unit suffering from SARS-CoV-2 infection from 14th March 2020 until 12th May 2020. Acute kidney injury was defined using the Kidney Disease Improving Global Outcome (KDIGO) criteria. The outcome analysis was assessed up to date as 3rd of September 2020. RESULTS A total of 81 patients admitted during this period. All patients had acute hypoxic respiratory failure and needed either noninvasive or invasive mechanical ventilatory support. Thirty-six patients (44%) had evidence of AKI (Stage I-33%, Stage II-22%, Renal Replacement Therapy (RRT)-44%). All patients with AKI stage III had RRT. Age, diabetes mellitus, immunosuppression, lymphopenia, high D-Dimer levels, increased APACHE II and SOFA scores, invasive mechanical ventilation and use of inotropic or vasopressor support were significantly associated with AKI. The peak AKI was at day 4 and mean duration of RRT was 12.5 days. The mortality was 25% for the AKI group compared to 6.7% in those without AKI. Among those received RRT and survived their illness, the renal function recovery is complete and back to baseline in all patients. CONCLUSION Acute kidney injury and renal replacement therapy is common in critically ill patients presenting with COVID-19. It is associated with increased severity of illness on admission to ICU, increased mortality and prolonged ICU and hospital length of stay. Recovery of renal function was complete in all survived patients.
Collapse
Affiliation(s)
- R Lowe
- General Intensive Care Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, England
| | - M Ferrari
- General Intensive Care Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, England
| | - M Nasim-Mohi
- General Intensive Care Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, England
| | - A Jackson
- General Intensive Care Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, England
- NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton / University of Southampton, Tremona Road, Southampton, SO16 6YD, England
| | - R Beecham
- General Intensive Care Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, England
| | - K Veighey
- Renal Medicine, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, England
| | - R Cusack
- General Intensive Care Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, England
- NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton / University of Southampton, Tremona Road, Southampton, SO16 6YD, England
- Faculty of Medicine, University of Southampton, University Hospital Southampton, Tremona Road, Southampton, SO16 6YD, England
| | - D Richardson
- General Intensive Care Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, England
| | - Mpw Grocott
- General Intensive Care Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, England
- NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton / University of Southampton, Tremona Road, Southampton, SO16 6YD, England
- Faculty of Medicine, University of Southampton, University Hospital Southampton, Tremona Road, Southampton, SO16 6YD, England
| | - Dzh Levett
- General Intensive Care Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, England
- NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton / University of Southampton, Tremona Road, Southampton, SO16 6YD, England
- Faculty of Medicine, University of Southampton, University Hospital Southampton, Tremona Road, Southampton, SO16 6YD, England
| | - A Dushianthan
- General Intensive Care Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, England.
- NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton / University of Southampton, Tremona Road, Southampton, SO16 6YD, England.
- Faculty of Medicine, University of Southampton, University Hospital Southampton, Tremona Road, Southampton, SO16 6YD, England.
| |
Collapse
|
15
|
Papadopoulos K, Sharma M, Hamilton E, Richardson D, Bashir B, Hodgson G, Ke N, Kang-Fortner Q, Zhou L, Zamboni W, Jolin H, Madigan C, Kelly M, Roth D. Early evidence of dose-dependent pharmacodynamic activity following treatment with SY-5609, a highly selective and potent oral CDK7 inhibitor, in patients with advanced solid tumors. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)31211-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
16
|
Richardson D, Zhan L, Reynolds M, Odom D, Hollis K, Mitra D, McRoy L, Hargis J. The impact of advanced or metastatic breast cancer or its treatment on productivity, energy, and physical activity among palbociclib participants of the MADELINE study. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)30805-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
17
|
Nichols MK, Andrew MK, Ye L, Hatchette TF, Ambrose A, Boivin G, Bowie W, Dos Santos G, Elsherif M, Green K, Haguinet F, Katz K, Leblanc J, Loeb M, MacKinnon-Cameron D, McCarthy A, McElhaney JE, McGeer A, Powis J, Richardson D, Semret M, Sharma R, Shinde V, Smyth D, Trottier S, Valiquette L, Webster D, McNeil SA. The Impact of Prior Season Vaccination on Subsequent Influenza Vaccine Effectiveness to Prevent Influenza-related Hospitalizations Over 4 Influenza Seasons in Canada. Clin Infect Dis 2020; 69:970-979. [PMID: 30508064 DOI: 10.1093/cid/ciy1009] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2018] [Accepted: 11/30/2018] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Recent studies have demonstrated the possibility of negative associations between prior influenza vaccines and subsequent influenza vaccine effectiveness (VE), depending on season and strain. We investigated this association over 4 consecutive influenza seasons (2011-2012 through 2014-2015) in Canada. METHODS Using a matched test-negative design, laboratory-confirmed influenza cases and matched test-negative controls admitted to hospitals were enrolled. Patients were stratified into 4 groups according to influenza vaccine history (not vaccinated current and prior season [referent], vaccinated prior season only, vaccinated current season only, and vaccinated both current and prior season). Conditional logistic regression was used to estimate VE; prior vaccine impact was assessed each season for overall effect and effect stratified by age (<65 years, ≥65 years) and type/subtype (A/H1N1, A/H3N2, influenza B). RESULTS Overall, mainly nonsignificant associations were observed. Trends of nonsignificant decreased VE among patients repeatedly vaccinated in both prior and current season relative to the current season only were observed in the A/H3N2-dominant seasons of 2012-2013 and 2014-2015. Conversely, in 2011-2012, during which B viruses circulated, and in 2013-2014, when A/H1N1 circulated, being vaccinated in both seasons tended to result in a high VE in the current season against the dominant circulating subtype. CONCLUSIONS Prior vaccine impact on subsequent VE among Canadian inpatients was mainly nonsignificant. Even in circumstances where we observed a trend of negative impact, being repeatedly vaccinated was still more effective than not receiving the current season's vaccine. These findings favor continuation of annual influenza vaccination recommendations, particularly in older adults. CLINICAL TRIALS REGISTRATION NCT01517191.
Collapse
Affiliation(s)
- M K Nichols
- Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia
| | - M K Andrew
- Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia
| | - L Ye
- Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia
| | - T F Hatchette
- Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia
| | - A Ambrose
- Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia
| | - G Boivin
- Centre Hospitalier Universitaire de Québec, Québec City, Canada
| | - W Bowie
- University of British Columbia, Vancouver, Canada
| | - G Dos Santos
- Business and Decision Life Sciences, Bruxelles, Belgium.,Present affiliation: GSK, Wavre, Belgium
| | - M Elsherif
- Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia
| | - K Green
- Mount Sinai Hospital, Toronto, Ontario, Canada
| | | | - K Katz
- North York General Hospital, Toronto
| | - J Leblanc
- Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia
| | - M Loeb
- McMaster University, Hamilton
| | - D MacKinnon-Cameron
- Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia
| | | | | | - A McGeer
- Mount Sinai Hospital, Toronto, Ontario, Canada
| | - J Powis
- Michael Garron Hospital, Toronto
| | | | - M Semret
- McGill University, Montreal, Québec
| | - R Sharma
- GSK, Mississauga, Ontario, Canada
| | - V Shinde
- GSK, King of Prussia, Pennsylvania.,Present affiliation: Novavax Vaccines, Washington, D.C
| | - D Smyth
- The Moncton Hospital, New Brunswick
| | - S Trottier
- Centre Hospitalier Universitaire de Québec, Québec City, Canada
| | | | - D Webster
- Saint John Hospital Regional Hospital, Dalhousie University, New Brunswick, Canada
| | - S A McNeil
- Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia
| | | |
Collapse
|
18
|
Greenwood A, Castellano T, Jordana B, Richardson D. Perspectives on Medical Marijuana: A Look at Society of Gynecology Oncology Providers. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.04.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
19
|
Schiavo S, Richardson D, Santa Mina D, Buryk-Iggers S, Uehling J, Carroll J, Clarke H, Djaiani C, Gershinsky M, Katznelson R. Hyperbaric oxygen and focused rehabilitation program: a feasibility study in improving upper limb motor function after stroke. Appl Physiol Nutr Metab 2020; 45:1345-1352. [PMID: 32574506 DOI: 10.1139/apnm-2020-0124] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Neuroplasticity and recovery after stroke can be enhanced by a rehabilitation program pertinent to upper limb motor function exercise and mental imagery (EMI) as well as hyperbaric oxygen therapy (HBOT). We assessed feasibility and safety of the combined approach utilizing both HBOT and EMI, and to derive preliminary estimates of its efficacy. In this randomized controlled trial, 27 patients with upper extremity hemiparesis at 3-48 months after stroke were randomized to receive either a complementary rehabilitation program of HBOT-EMI (intervention group), or EMI alone (control group). Feasibility and safety were assessed as total session attendance, duration of sessions, attrition rates, missing data, and intervention-related adverse events. Secondary clinical outcomes were assessed with both objective tools and self-reported measures at baseline, 8 weeks (end of treatment), and 12-weeks follow-up. Session attendance, duration, and attrition rate did not differ between the groups; there were no serious adverse events. Compared with baseline, there were significant sustained improvements of objective and subjective outcomes' measures in the intervention group, and a single improvement in an objective measure in the control group. Between-group outcome comparisons were not statistically significant. This study demonstrated that the combination HBOT-EMI was a safe and feasible approach in patients recovering from chronic stroke. There were also trends for improved motor function of the affected upper limb after the treatments. ClinicalTrials.gov registration no.: NCT02666469. Novelty HBOT combined with an upper limb exercise and mental imagery rehabilitation program is feasible and safe in chronic stroke patients. This combined approach showed trends for improved functional recovery.
Collapse
Affiliation(s)
- S Schiavo
- Hyperbaric Medicine Unit, Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Toronto, ON M5G 2C4, Canada
| | - D Richardson
- Stroke Rehabilitation Clinic, Toronto Rehabilitation Institute, Toronto, ON M5G 2C4, Canada
| | - D Santa Mina
- Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON M5G 2C1, Canada.,Department of Surgery, Faculty of Medicine, University of Toronto.,Department of Supportive Care, Princess Margaret Cancer Centre Toronto, ON M5G 2C1, Canada
| | - S Buryk-Iggers
- Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON M5G 2C1, Canada
| | - J Uehling
- Hyperbaric Medicine Unit, Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Toronto, ON M5G 2C4, Canada
| | - J Carroll
- Hyperbaric Medicine Unit, Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Toronto, ON M5G 2C4, Canada
| | - H Clarke
- Hyperbaric Medicine Unit, Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Toronto, ON M5G 2C4, Canada
| | - C Djaiani
- Hyperbaric Medicine Unit, Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Toronto, ON M5G 2C4, Canada
| | - M Gershinsky
- Hyperbaric Medicine Unit, Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Toronto, ON M5G 2C4, Canada
| | - R Katznelson
- Hyperbaric Medicine Unit, Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Toronto, ON M5G 2C4, Canada
| |
Collapse
|
20
|
Son J, Carr C, Chambers LM, Michener C, Meng Y, Yen T, Beavis A, Stone R, Wethington S, Burkett W, Richardson D, Staley AS, Ahn S, Gehrig P, Torres D, Dowdy S, Sullivan M, Modesitt S, Watson C, Secord A, Veade A, Havrilesky L, Loreen A, Griffin K, Jackson A, Fader AN, Ricci S. Adjuvant treatment in high intermediate risk early stage endometrial cancer. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2019.11.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
21
|
Asperger H, Ludescher M, Stamm N, Cieslik JP, Hofmann U, Zanger U, Kovacevic Z, Richardson D, Ruckhäberle E, Fehm T, Niederacher D, Neubauer H. Abstract P2-04-02: Progesterone receptor membrane component 1 - A novel key regulator in lipid homeostasis drives oncogenic signaling resulting in breast cancer progression. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p2-04-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: PGRMC1 (progesterone receptor membrane component 1) is a highly conserved heme binding protein which is overexpressed especially in hormone receptor positive breast cancer and plays an important role in breast cancer carcinogenesis. Nevertheless, little is known about the mechanisms by which PGRMC1 drives tumor progression. Based on our previous studies on the involvement of PGRMC1 in cholesterol metabolism we describe a potential mechanism by which PGRMC1 can increase lipid metabolism and alter EGFR signaling.
Methods: To obtain PGRMC1 overexpressing cell lines, MCF7, T47D and MDA cells were stably transfected with expression plasmid pcDNA3.1. containing HA-tagged PGRMC1. As a control, cells transfected with the empty plasmid were used.To investigate the role of PGRMC1 in breast cancer progression, expression of genes involved in lipid metabolism were quantified by qPCR. Subsequent lipid and cholesterol levels as well as lipid raft expression were measured by flow cytometry in various breast cancer cell lines overexpressing PGRMC1 compared to empty vector control. Since many studies show that EGFR is enriched in lipid rafts, we further investigated alteration of EGFR/HER2 signaling through PGRMC1 overexpression via western blot and immunofluorescence analyses. The impact of lipid inhibition on tumor progression was analyzed by viability assays.
Results: PGRMC1 overexpression resulted in higher levels of mRNA coding for proteins responsible for lipid homeostasis (SREPF1, SREBF2), lipid uptake (LDLR) and lipid synthesis (FASN, HMGCS, SCD, ACAT) leading to higher levels of neutral lipids, estradiol and cholesterol. Furthermore, PGRMC1 overexpressing hormone receptor positive cells show increased lipid raft formation with higher expression of EGFR/HER2 and altered EGFR/HER2 signaling. PGRMC1 overexpressing cells are more sensitive to a simvastatin treatment, which indicates a higher dependence of PGRMC1 overexpressing cells on cholesterol synthesis.
Conclusion: Cholesterol and lipid metabolism play an important role in breast carcinogenesis. Our recent studies underline the effects of PGRMC1 on increasing lipid synthesis and uptake thereby altering oncogenic signaling. PGRMC1 overexpressing breast cancer cells could be particularly suitable for a statin treatment.
Citation Format: Hannah Asperger, Marina Ludescher, Nadia Stamm, Jan-Philipp Cieslik, Ute Hofmann, Ulrich Zanger, Zaklina Kovacevic, Des Richardson, Eugen Ruckhäberle, Tanja Fehm, Dieter Niederacher, Hans Neubauer. Progesterone receptor membrane component 1 - A novel key regulator in lipid homeostasis drives oncogenic signaling resulting in breast cancer progression [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-04-02.
Collapse
Affiliation(s)
- Hannah Asperger
- 1Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University, Düsseldorf, Germany
| | - Marina Ludescher
- 1Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University, Düsseldorf, Germany
| | - Nadia Stamm
- 1Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University, Düsseldorf, Germany
| | - Jan-Philipp Cieslik
- 1Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University, Düsseldorf, Germany
| | - Ute Hofmann
- 2Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
| | - Ulrich Zanger
- 2Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
| | - Zaklina Kovacevic
- 3Department of Pathology, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
| | - Des Richardson
- 3Department of Pathology, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
| | - Eugen Ruckhäberle
- 1Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University, Düsseldorf, Germany
| | - Tanja Fehm
- 1Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University, Düsseldorf, Germany
| | - Dieter Niederacher
- 1Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University, Düsseldorf, Germany
| | - Hans Neubauer
- 1Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University, Düsseldorf, Germany
| |
Collapse
|
22
|
LeBlanc JJ, ElSherif M, Mulpuru S, Warhuus M, Ambrose A, Andrew M, Boivin G, Bowie W, Chit A, Dos Santos G, Green K, Halperin SA, Hatchette TF, Ibarguchi B, Johnstone J, Katz K, Langley JM, Lagacé-Wiens P, Loeb M, Lund A, MacKinnon-Cameron D, McCarthy A, McElhaney JE, McGeer A, Poirier A, Powis J, Richardson D, Semret M, Shinde V, Smyth D, Trottier S, Valiquette L, Webster D, Ye L, McNeil S. Validation of the Seegene RV15 multiplex PCR for the detection of influenza A subtypes and influenza B lineages during national influenza surveillance in hospitalized adults. J Med Microbiol 2020; 69:256-264. [PMID: 31264957 PMCID: PMC7431100 DOI: 10.1099/jmm.0.001032] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Accepted: 06/16/2019] [Indexed: 01/04/2023] Open
Abstract
Background. The Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN SOS) has been performing active influenza surveillance since 2009 (ClinicalTrials.gov identifier: NCT01517191). Influenza A and B viruses are identified and characterized using real-time reverse-transcriptase polymerase chain reaction (RT-PCR), and multiplex testing has been performed on a subset of patients to identify other respiratory virus aetiologies. Since both methods can identify influenza A and B, a direct comparison was performed.Methods. Validated real-time RT-PCRs from the World Health Organization (WHO) to identify influenza A and B viruses, characterize influenza A viruses into the H1N1 or H3N2 subtypes and describe influenza B viruses belonging to the Yamagata or Victoria lineages. In a subset of patients, the Seeplex RV15 One-Step ACE Detection assay (RV15) kit was also used for the detection of other respiratory viruses.Results. In total, 1111 nasopharyngeal swabs were tested by RV15 and real-time RT-PCRs for influenza A and B identification and characterization. For influenza A, RV15 showed 98.0 % sensitivity, 100 % specificity and 99.7 % accuracy. The performance characteristics of RV15 were similar for influenza A subtypes H1N1 and H3N2. For influenza B, RV15 had 99.2 % sensitivity, 100 % specificity and 99.8 % accuracy, with similar assay performance being shown for both the Yamagata and Victoria lineages.Conclusions. Overall, the detection of circulating subtypes of influenza A and lineages of influenza B by RV15 was similar to detection by real-time RT-PCR. Multiplex testing with RV15 allows for a more comprehensive respiratory virus surveillance in hospitalized adults, without significantly compromising the reliability of influenza A or B virus detection.
Collapse
Affiliation(s)
- J. J. LeBlanc
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - M. ElSherif
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - S. Mulpuru
- Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
| | - M. Warhuus
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - A. Ambrose
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - M. Andrew
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - G. Boivin
- Centre Hospitalier Universitaire de Québec, QC, Canada
| | - W. Bowie
- University of British Columbia, Vancouver, BC, Canada
| | - A. Chit
- Sanofi Pasteur, Swiftwater, PA, USA
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
| | - G. Dos Santos
- Business & Decision Life Sciences (on behalf of GSK), Bruxelles, Belgium
- Present address: GSK, Wavre, Belgium
| | - K. Green
- Mount Sinai Hospital, Toronto, ON, Canada
| | - S. A. Halperin
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - T. F. Hatchette
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - B. Ibarguchi
- GSK, Mississauga, ON, Canada
- Present address: Bayer, Inc., Mississauga, Ontario, Canada
| | - J. Johnstone
- Public Health Ontario and University of Toronto, Toronto, ON, Canada
| | - K. Katz
- North York General Hospital, Toronto, ON, Canada
| | - J. M. Langley
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | | | - M. Loeb
- Public Health Ontario and University of Toronto, Toronto, ON, Canada
| | - A. Lund
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - D. MacKinnon-Cameron
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - A. McCarthy
- Ottawa Hospital General, Ottawa, Ontario, Canada
| | - J. E. McElhaney
- Health Sciences North Research Institute, Sudbury, ON, Canada
| | - A. McGeer
- Mount Sinai Hospital, Toronto, ON, Canada
| | - A. Poirier
- Centre Intégré Universitaire de Santé et Services Sociaux, Quebec, QC, Canada
| | - J. Powis
- Toronto East General Hospital, Toronto, ON, Canada
| | | | - M. Semret
- McGill University, Montreal, QC, Canada
| | - V. Shinde
- GSK, King of Prussia, PA, USA
- Present address: Novavax Vaccines, Washington, DC, USA
| | - D. Smyth
- The Moncton Hospital, Moncton, NB, Canada
| | - S. Trottier
- Centre Hospitalier Universitaire de Québec, QC, Canada
| | | | | | - L. Ye
- Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, NS, Canada
| | - S. A. McNeil
- Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
| |
Collapse
|
23
|
Appelhans BM, French SA, Bradley LE, Lui K, Janssen I, Richardson D. CHECK: A randomized trial evaluating the efficacy and cost-effectiveness of home visitation in pediatric weight loss treatment. Contemp Clin Trials 2019; 88:105891. [PMID: 31740429 DOI: 10.1016/j.cct.2019.105891] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Revised: 11/06/2019] [Accepted: 11/13/2019] [Indexed: 01/15/2023]
Abstract
BACKGROUND Socioeconomically-disadvantaged households have a high prevalence of pediatric overweight/obesity, and also face barriers to accessing weight loss treatment in healthcare settings. Delivering family-based pediatric weight loss treatment in the home setting may enhance its efficacy by facilitating treatment attendance, enabling more tailored treatment recommendations informed by observations of the home environment, and increasing accountability. This paper describes the design of the Creating Health Environments for Chicago Kids (CHECK) Trial, which evaluates the efficacy, cost-effectiveness, and mechanisms of home visitation in family-based pediatric weight loss treatment for children in low-income households. DESIGN CHECK is a two-arm, parallel group, randomized controlled trial that is enrolling N = 266 children, ages 6-12 y, who have overweight/obesity (BMI percentile ≥85) and live in a low-income household. Participants are randomized in a 1:1 ratio to either standard of care family-based weight loss treatment delivered in the home, or the identical intervention delivered in an academic medical center. The primary outcome is change in child BMI z-score from baseline to 12 months. Program delivery costs are rigorously documented to enable cost-effectiveness analyses from the societal and payer perspectives. Objectively-documented changes to the home environment and aspects of intervention delivery (e.g., hours of in-person contact received, quantity of behavioral goals set per session) will be tested as hypothesized treatment mechanisms. IMPLICATIONS Findings will inform the design of future interventions, and treatment dissemination decisions by public health agencies and third-party payers. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT03195790.
Collapse
Affiliation(s)
- B M Appelhans
- Department of Preventive Medicine, Rush University Medical Center, United States of America; Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, United States of America.
| | - S A French
- Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, United States of America
| | - L E Bradley
- Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, United States of America
| | - K Lui
- Department of Pediatrics, Rush University Medical Center, United States of America
| | - I Janssen
- Department of Preventive Medicine, Rush University Medical Center, United States of America
| | - D Richardson
- Department of Preventive Medicine, Rush University Medical Center, United States of America; Department of Mathematics and Computer Science, Lake Forest College, United States of America
| |
Collapse
|
24
|
O'Malley D, Richardson D, Vergote I, Gilbert L, Martin L, Mantia-Smaldone G, Castro C, Provencher D, Matulonis U, Malek K, Moore K. Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Affiliation(s)
- C Fitzpatrick
- Clinic 16 Royal Northshore Hospital Sydney Australia
- Brighton & Sussex University Hospitals NHS Trust Brighton UK
| | - M Lowe
- Brighton & Sussex University Hospitals NHS Trust Brighton UK
| | - D Richardson
- Brighton & Sussex University Hospitals NHS Trust Brighton UK
- Brighton & Sussex Medical School Brighton UK
| |
Collapse
|
26
|
Hampton P, Richardson D, Brown S, Goodhead C, Montague K, Olivier P. Usability testing of MySkinSelfie: a mobile phone application for skin self-monitoring. Clin Exp Dermatol 2019; 45:73-78. [PMID: 31021009 DOI: 10.1111/ced.13995] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/19/2019] [Indexed: 12/01/2022]
Abstract
Teledermatology generally involves doctors taking images of patients; however, patients increasingly want to own or have easy access to their health data. MySkinSelfie ( http://myskinselfie.com) is a mobile phone application (app) designed to improve the quality, consistency and accessibility of patient-held photos, and was developed to give patients the ability to generate and hold their own skin images to help guide their skin care. This study assessed the usability of this app in a cohort of patients attending a National Health Service Dermatology clinic. Patients were asked to use the app but were not given specific tasks to achieve. Of the 102 patients recruited, 32 downloaded the app and registered an account, 21 took at least one photo (median 5, range 1-103) and 19 completed the usability questionnaire. The majority of questionnaire respondents found the app easy to use but were more neutral on whether it really helped them to manage their skin problem. MySkinSelfie has been shown to be easy to use. Self-monitoring of skin problems may be useful for a subset of patients, and this is likely to depend on diagnosis, age and other patient factors.
Collapse
Affiliation(s)
- P Hampton
- Department of Dermatology, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK
| | - D Richardson
- Open Lab, School of Computing Science, Newcastle University, Newcastle upon Tyne, UK
| | - S Brown
- Department of Dermatology, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK
| | - C Goodhead
- Department of Dermatology, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK
| | - K Montague
- Open Lab, School of Computing Science, Newcastle University, Newcastle upon Tyne, UK
| | - P Olivier
- Open Lab, School of Computing Science, Newcastle University, Newcastle upon Tyne, UK
| |
Collapse
|
27
|
Williams D, Reicher I, Mohammed H, Richardson D. Secondary adrenal insufficiency from steroid use and co-prescribing of cytochrome p450 3A4 inhibitors. HIV Med 2019; 20:e10-e11. [PMID: 30924569 DOI: 10.1111/hiv.12723] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- D Williams
- Brighton & Sussex University Hospitals NHS Trust, Brighton, UK
| | - I Reicher
- Brighton & Sussex Medical School, Brighton, UK
| | - H Mohammed
- Chelsea and Westminster NHS Trust, London, UK
| | - D Richardson
- Brighton & Sussex University Hospitals NHS Trust, Brighton, UK.,Brighton & Sussex Medical School, Brighton, UK
| |
Collapse
|
28
|
Fitzpatrick C, Lowe M, Richardson D. Sexually transmitted infection testing and rates in men who have sex with men (
MSM
) using
HIV
pre‐exposure prophylaxis. HIV Med 2019; 20:e12. [DOI: 10.1111/hiv.12736] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- C Fitzpatrick
- Brighton & Sussex University Hospitals NHS Trust Brighton UK
| | - M Lowe
- Brighton & Sussex University Hospitals NHS Trust Brighton UK
| | - D Richardson
- Brighton & Sussex University Hospitals NHS Trust Brighton UK
- Brighton & Sussex Medical School Brighton UK
| |
Collapse
|
29
|
Odom D, Mitra D, Hollis K, Richardson D, Kaye JA, McRoy L. Abstract P6-18-27: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Odom D, Mitra D, Hollis K, Richardson D, Kaye JA, McRoy L. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-27.
Collapse
Affiliation(s)
- D Odom
- RTI Health Solutions, Research Triangle Park, NC; Pfizer, Inc., New York, NY
| | - D Mitra
- RTI Health Solutions, Research Triangle Park, NC; Pfizer, Inc., New York, NY
| | - K Hollis
- RTI Health Solutions, Research Triangle Park, NC; Pfizer, Inc., New York, NY
| | - D Richardson
- RTI Health Solutions, Research Triangle Park, NC; Pfizer, Inc., New York, NY
| | - JA Kaye
- RTI Health Solutions, Research Triangle Park, NC; Pfizer, Inc., New York, NY
| | - L McRoy
- RTI Health Solutions, Research Triangle Park, NC; Pfizer, Inc., New York, NY
| |
Collapse
|
30
|
Vandi LJ, Chan CM, Werker A, Richardson D, Laycock B, Pratt S. Experimental data for extrusion processing and tensile properties of poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) polymer and wood fibre reinforced PHBV biocomposites. Data Brief 2019; 22:687-692. [PMID: 30671517 PMCID: PMC6327731 DOI: 10.1016/j.dib.2018.12.084] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2018] [Revised: 12/20/2018] [Accepted: 12/26/2018] [Indexed: 11/05/2022] Open
Abstract
This article features a large database on different extrusion processing conditions and the resulting tensile properties of poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) and wood fibre reinforced biocomposites. The data presented here corresponds to a comprehensive design of experiments conducted separately for both neat PHBV polymer and wood–PHBV composites, in which the effects of temperature profile, screw speed, feeding rate, feeding method, screw configuration, and wood contents (wood–PHBV composites only) of 10, 20, 30, and 40 wt% wood content were examined. For each processing condition, 5 specimens were tested under uniaxial tensile loading. Here we provide the complete set of extrusion parameters, including the observed screw torque, residence time and material output. Individual stress–strain curves for each specimens are provided, along with their calculated elastic modulus, strength, and strain at maximum load. The data is also provided as support material for the research article: “Extrusion of wood fibre reinforced Poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) biocomposites: statistical analysis of the effect of processing conditions on mechanical performance” (Vandi et al., 2018).
Collapse
Affiliation(s)
- Luigi-Jules Vandi
- School of Chemical Engineering, University of Queensland, St. Lucia, Queensland, Australia
| | - Clement Matthew Chan
- School of Chemical Engineering, University of Queensland, St. Lucia, Queensland, Australia
| | - Alan Werker
- School of Chemical Engineering, University of Queensland, St. Lucia, Queensland, Australia.,Promiko AB, Lomma, Sweden
| | - Des Richardson
- Norske Skog Paper Mills (Australia) Ltd, Boyer, Tasmania, Australia
| | - Bronwyn Laycock
- School of Chemical Engineering, University of Queensland, St. Lucia, Queensland, Australia
| | - Steven Pratt
- School of Chemical Engineering, University of Queensland, St. Lucia, Queensland, Australia
| |
Collapse
|
31
|
Vandi LJ, Chan CM, Werker A, Richardson D, Laycock B, Pratt S. Extrusion of wood fibre reinforced poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) biocomposites: Statistical analysis of the effect of processing conditions on mechanical performance. Polym Degrad Stab 2019. [DOI: 10.1016/j.polymdegradstab.2018.10.015] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
32
|
Richardson D, Bell C. Public health interventions for reducing HIV, hepatitis B and hepatitis C infections in people who inject drugs. Public Health Action 2018; 8:153. [PMID: 30775273 PMCID: PMC6361494 DOI: 10.5588/pha.18.0093-ed] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Accepted: 11/12/2018] [Indexed: 01/19/2023] Open
Affiliation(s)
- D Richardson
- Brighton & Sussex University Hospitals National Health Service Trust, Brighton & Sussex Medical School, Brighton, UK
| | - C Bell
- Adelaide Sexual Health Centre, Adelaide, South Australia, Australia
| |
Collapse
|
33
|
Affiliation(s)
- D Williams
- Brighton & Sussex University Hospitals NHS Trust, Brighton, UK
| | - J Scott
- Brighton & Sussex Medical School, Brighton, UK
| | - D Richardson
- Brighton & Sussex University Hospitals NHS Trust, Brighton, UK.,Brighton & Sussex Medical School, Brighton, UK
| | - E Kingdon
- Brighton & Sussex University Hospitals NHS Trust, Brighton, UK
| |
Collapse
|
34
|
Harrison PW, Fan J, Richardson D, Clarke L, Zerbino D, Cochrane G, Archibald AL, Schmidt CJ, Flicek P. FAANG, establishing metadata standards, validation and best practices for the farmed and companion animal community. Anim Genet 2018; 49:520-526. [PMID: 30311252 PMCID: PMC6334167 DOI: 10.1111/age.12736] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/11/2018] [Indexed: 12/30/2022]
Abstract
The Functional Annotation of ANimal Genomes (FAANG) project aims, through a coordinated international effort, to provide high quality functional annotation of animal genomes with an initial focus on farmed and companion animals. A key goal of the initiative is to ensure high quality and rich supporting metadata to describe the project's animals, specimens, cell cultures and experimental assays. By defining rich sample and experimental metadata standards and promoting best practices in data descriptions, deposition and openness, FAANG champions higher quality and reusability of published datasets. FAANG has established a Data Coordination Centre, which sits at the heart of the Metadata and Data Sharing Committee. It continues to evolve the metadata standards, support submissions and, crucially, create powerful and accessible tools to support deposition and validation of metadata. FAANG conforms to the findable, accessible, interoperable, and reusable (FAIR) data principles, with high quality, open access and functionally interlinked data. In addition to data generated by FAANG members and specific FAANG projects, existing datasets that meet the main—or more permissive legacy—standards are incorporated into a central, focused, functional data resource portal for the entire farmed and companion animal community. Through clear and effective metadata standards, validation and conversion software, combined with promotion of best practices in metadata implementation, FAANG aims to maximise effectiveness and inter‐comparability of assay data. This supports the community to create a rich genome‐to‐phenotype resource and promotes continuing improvements in animal data standards as a whole.
Collapse
Affiliation(s)
- P W Harrison
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK
| | - J Fan
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK
| | - D Richardson
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK
| | - L Clarke
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK
| | - D Zerbino
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK
| | - G Cochrane
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK
| | - A L Archibald
- The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, UK
| | - C J Schmidt
- Department of Animal and Food Sciences, College of Agriculture and Natural Resources, University of Delaware, Newark, DE, 19716, USA
| | - P Flicek
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK
| |
Collapse
|
35
|
Blanchette P, Chung H, Pritchard K, Earle C, Campitelli M, Crowcroft N, Gubbay J, Karnauchow T, Katz K, McGeer A, McNally D, Richardson D, Richardson S, Rosella L, Simor A, Smieja M, Zahariadis G, Campigotto A, Kwong J. Influenza vaccine effectiveness among cancer patients: A population-based study using health administrative and laboratory testing data from Ontario, Canada. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy297.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Hardesty M, Hope J, Krivak T, Chen J, Wainszelbaum M, Gupta D, Richardson D. OVARIO: A single-arm, open-label phase II study of maintenance therapy with niraparib + bevacizumab (bev) in patients (pts) with advanced ovarian cancer (OC) after response to frontline platinum-based chemotherapy (chemo). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy285.206] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Vandi LJ, Chan CM, Werker A, Richardson D, Laycock B, Pratt S. Wood-PHA Composites: Mapping Opportunities. Polymers (Basel) 2018; 10:polym10070751. [PMID: 30960676 PMCID: PMC6403649 DOI: 10.3390/polym10070751] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2018] [Revised: 07/02/2018] [Accepted: 07/03/2018] [Indexed: 11/16/2022] Open
Abstract
Polyhydroxyalkanoate (PHA) biopolymers are emerging as attractive new sustainable polymers due to their true biodegradability and highly tuneable mechanical properties. However, despite significant investments, commercialisation barriers are hindering the capacity growth of PHA. In this work, we investigated the market potential for wood plastic composites (WPCs) based on PHAs. We considered the latest global production capacity of PHAs, estimated at 66,000 tonnes/year, and examined the implications of using PHAs for WPC production on the WPC market. Results indicate that a hypothetical usage of the current global PHA production for WPC manufacture would only represent the equivalent of 4.4% of the global WPC market, which is currently experiencing a 10.5% compounded annual growth rate. An economic assessment revealed that a wood-PHA composite as a drop-in alternative WPC product could cost as little as 37% of the cost of its neat PHA counterpart. Thus, WPCs with PHA offer a means to access benefits of PHA in engineering applications at reduced costs; however, further developments are required to improve strain at failure. The successful adoption of wood-PHA composites into the market is furthermore reliant on support from public sector to encourage biodegradable products where recycling is not a ready solution.
Collapse
Affiliation(s)
- Luigi-Jules Vandi
- School of Chemical Engineering, University of Queensland, St. Lucia, QSD 4072, Australia.
| | - Clement Matthew Chan
- School of Chemical Engineering, University of Queensland, St. Lucia, QSD 4072, Australia.
| | - Alan Werker
- School of Chemical Engineering, University of Queensland, St. Lucia, QSD 4072, Australia.
- Promiko AB, 23442 Lomma, Sweden.
| | - Des Richardson
- Norske Skog Paper Mills (Australia) Ltd., Boyer, TAS 7140, Australia.
| | - Bronwyn Laycock
- School of Chemical Engineering, University of Queensland, St. Lucia, QSD 4072, Australia.
| | - Steven Pratt
- School of Chemical Engineering, University of Queensland, St. Lucia, QSD 4072, Australia.
| |
Collapse
|
38
|
Merlot A, Shafie N, Lim E, Chen A, Sahni S, Yu Y, Richardson D. PO-460 Targeting endoplasmic reticulum stress using thiosemicarbazones to suppress cancer progression. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
39
|
Menezes SV, Kovacevic Z, Richardson D. Abstract A165: Novel thiosemicarbazone, Dp44mT, promotes NDRG1 to downregulate oncogenic signaling pathways in cancer. Mol Cancer Ther 2018. [DOI: 10.1158/1535-7163.targ-17-a165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The novel thiosemicarbazone, Dp44mT, has shown potent anticancer activity against various cancer types. The activity of this agent is, at least in part, mediated by its ability to upregulate the growth and metastasis suppressor, N-myc Downstream Regulated Gene 1 (NDRG1). NDRG1 inhibits cell proliferation, migration, and invasion by negatively regulating numerous oncogenic signaling pathways. However, the mechanisms by which NDRG1 modulates all these pathways remain to be elucidated. To examine how NDRG1 and Dp44mT affect multiple signalling pathways, we assessed their effects on the ErbB-family of receptor tyrosine kinases, namely epidermal growth factor receptor (EGFR), human epidermal growth factor 2 (HER2) and human epidermal growth factor receptor 3 (HER3), as these molecules are key regulators of downstream oncogenic signaling. Methods: PANC1 pancreatic and HT-29 colon human cancer cells were utilized to examine the effects of NDRG1 and Dp44mT on EGFR, HER2, and HER3 levels, localization, and phosphorylation in vitro. PANC1 xenografts were also utilized to examine the effects of Dp44mT on these molecules in vivo. Results: For the first time, we demonstrate that NDRG1 and Dp44mT markedly inhibit the expression, localization, and activation of EGFR, HER2, and HER3. NDRG1 also reduced activation of the MAPK-signalling pathway, which is downstream of the ErbB family of receptors. Further, the anticancer agent, Dp44mT, significantly reduced expression of EGFR, HER2, and HER3 in vivo. Conclusions: This study demonstrates for the first time that the novel thiosemicarbazone, Dp44mT, inhibits the ErbB family of proteins through its upregulation of NDRG1, providing an interesting insight into the mechanisms behind its compelling anticancer activity.
Citation Format: Sharleen V. Menezes, Zaklina Kovacevic, Des Richardson. Novel thiosemicarbazone, Dp44mT, promotes NDRG1 to downregulate oncogenic signaling pathways in cancer [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A165.
Collapse
|
40
|
Merlot A, Shafie N, Porter G, Sahni S, Richardson D. Abstract B143: The formation of redox active complexes is important for the induction of the UPR by Dp44mT. Mol Cancer Ther 2018. [DOI: 10.1158/1535-7163.targ-17-b143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Activation of the unfolded protein response (UPR) has been demonstrated in several cancer types. This has been attributed to two main factors, namely: (1) intrinsic factors (e.g., hyperactivation of oncogenes) and (2) extrinsic factors (i.e., the hostile microenvironment of tumors). This activation of the UPR has been linked to oncogenic transformation and cancer development. Considering the UPR has been identified as an adverse marker for prognosis, a better understanding of the role of the UPR in the outcome of cancer therapeutics will offer new opportunities to improve existing treatment strategies. Notably, the anticancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazones (Dp44mT), has been shown to activate the UPR, specifically PERK, IRE1α, and ATF6. This agent has been demonstrated to possess potent and selective antitumor and antimetastatic activity. In fact, this class of agents is currently in clinical trials for the treatment of advanced solid tumors (NCT02688101). Hence, the role of the UPR in the anticancer activity of Dp44mT and the importance of the formation of redox active complexes by Dp44mT was assessed. Studies have demonstrated that Dp44mT activates the main arms of the UPR, namely PERK, IRE1α, and ATF6, inducing proapoptotic pathways (e.g., CHOP, caspase 3), while inhibiting the prosurvival signals, i.e., XBP1s, p58IPK. Considering this and the induction of ROS by Dp44mT, experiments assessed the role of the formation of redox active complexes by Dp44mT in inducing UPR activation using the glutathione synthesis inhibitor, buthionine sulfoximine (BSO), and the antioxidant, N-acetyl-L-cysteine (NAC), that potentiates and inhibits oxidative stress, respectively, in human SK-N-MC neuroepithelioma cells. Importantly, Western blot analysis demonstrated that BSO or NAC alone did not significantly induce or alter the expression of the UPR mediators, p-eIF2α, p-IRE1α, cleaved ATF6, and p-CaMKII. Incubation of cells with Dp44mT and BSO potentiated Dp44mT-mediated activation of the UPR, increasing levels of p-eIF2α, p-IRE1α, cleaved ATF6, and p-CaMKII relative to the control. In contrast, NAC and Dp44mT treatment reduced the expression of these UPR mediators in comparison to cells treated with Dp44mT alone. Hence, BSO enhanced the activation of the UPR pathways by Dp44mT, while the antioxidant NAC inhibited this process. This suggested that the formation of ROS is important for Dp44mT-mediated UPR activation. MTT studies were also performed to determine the role of the main UPR arms, PERK or IRE1α, in the antiproliferative activity of Dp44mT. PERK or IRE1α silencing increased the effectiveness of Dp44mT by significantly (p<0.01) reducing its IC50, suggesting these proteins are important for cell survival and are indicators of therapeutic outcomes. In conclusion, the formation of redox active complexes is important for the induction of the UPR by Dp44mT. Additionally, PERK and IRE1α are important mediators that enhance cell survival and silencing these proteins increases the antiproliferative activity of Dp44mT. This may be related to their role in autophagy. Considering the activation of the UPR in cancers, it is crucial to continue to characterize the effect of the UPR on cancer therapeutics to better predict clinical outcomes and the subpopulations of patients that will greatly benefit from this type of therapy.
Citation Format: Angelica Merlot, Nurul Shafie, Georgia Porter, Sumit Sahni, Des Richardson. The formation of redox active complexes is important for the induction of the UPR by Dp44mT [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B143.
Collapse
Affiliation(s)
| | | | | | - Sumit Sahni
- 1University of Sydney, Sydney, NSW, Australia
| | | |
Collapse
|
41
|
Palavalli Parsons L, Lin K, Miller D, Richardson D, Carlson M, Kehoe S, Lea J. Family History of Cancer Shows Improved Survival in Uterine Papillary Serous Carcinoma. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.07.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
42
|
Park K, Kovacevic Z, Richardson D. Deciphering the regulation of the metastasis suppressor, NDRG1 in different cancer-types and its functional implications. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx361.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Dugena O, Bujtar P, Robertson B, Scrimshire A, Brannigan K, Richardson D, Mohanrao S, Burn S, Parks C, Sinha A, Duncan C. Understanding craniofacial dermoids: 10-year experience at the Liverpool Craniofacial Centre. Int J Oral Maxillofac Surg 2017. [DOI: 10.1016/j.ijom.2017.02.874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
44
|
Faisal M, Howes R, Steyerberg EW, Richardson D, Mohammed MA. Using routine blood test results to predict the risk of death for emergency medical admissions to hospital: an external model validation study. QJM 2017; 110:27-31. [PMID: 27486263 DOI: 10.1093/qjmed/hcw110] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2016] [Revised: 05/19/2016] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND The Biochemistry and Haematology Outcome Model (BHOM) relies on the results from routine index blood tests to predict the patient risk of death. We aimed to externally validate the BHOM model. METHOD We considered all emergency adult medical patients who were discharged from Northern Lincolnshire and Goole (NLAG) hospital in 2014. We compared patient characteristics between NLAG (the validation sample) and the hospital where BHOM was developed. We evaluated the predictive performance, according to discriminative ability (with a concordance statistic, c), and calibration (agreement between observed and predicted risk). RESULT There were 29 834 emergency discharges of which 24 696 (83%) had complete data. In comparison with the development sample, the NLAG sample was similar in age, blood test results, but experienced a lower mortality (4.7 vs. 8.7%). When applied to NLAG, the BHOM model had good discrimination (c-statistic 0.83 [95% CI 0.823-0.842]). Calibration was good overall, although the BHOM model overpredicted for lowest (<5%, observed = 229, predicted = 286) and highest (≥50%, observed = 31, predicted = 49) risk groups, even after recalibrating for the differences in baseline risk of death. CONCLUSION Differences in patient case-mix profile and baseline risk of death need to be considered before the BHOM model can be used in another hospital. After re-calibrating for the baseline difference in risk the BHOM model had good discrimination but less adequate calibration.
Collapse
Affiliation(s)
- M Faisal
- From the Faculty of Health Studies, University of Bradford, Bradford, UK
- Bradford Teaching Hospitals NHS Foundation Trust Bradford Institute for Health Research, Bradford, UK
| | - R Howes
- Northern Lincolnshire and Goole NHS Foundation, Diana, Princess of Wales Hospital, Grimsby, North East Lincolnshire, UK
| | - E W Steyerberg
- Department of Public Health, Erasmus University, Rotterdam, The Netherlands
| | - D Richardson
- Department of Renal Medicine, York District Hospital, York, UK
| | - M A Mohammed
- From the Faculty of Health Studies, University of Bradford, Bradford, UK
- Bradford Teaching Hospitals NHS Foundation Trust Bradford Institute for Health Research, Bradford, UK
| |
Collapse
|
45
|
Bedell S, Manders D, Miller D, Lea J, Kehoe S, Richardson D, Carlson M. The Opinions and Practices of Providers Toward the Sexual Issues of Cervical Cancer Patients Undergoing Treatment. Gynecol Oncol 2016. [DOI: 10.1016/j.ygyno.2016.08.284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
46
|
Crim A, Gillen J, Liu C, Roane B, Ding K, Richardson D, Moore K. Prognostic Importance of Progression Free Survival Interval in Patients with IVB Endometrial Cancer Treated with Platinum-Based Therapy. Gynecol Oncol 2016. [DOI: 10.1016/j.ygyno.2016.08.281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
47
|
Affiliation(s)
- N Mody
- King's College Hospital NHS Foundation Trust; London UK
| | - N Perry
- Brighton & Sussex University Hospitals NHS Trust; Brighton UK
- Brighton & Sussex Medical School; Brighton UK
| | - D Richardson
- Brighton & Sussex University Hospitals NHS Trust; Brighton UK
- Brighton & Sussex Medical School; Brighton UK
| | - L Barbour
- Brighton & Sussex University Hospitals NHS Trust; Brighton UK
| | - M Fisher
- Brighton & Sussex University Hospitals NHS Trust; Brighton UK
- Brighton & Sussex Medical School; Brighton UK
| | | |
Collapse
|
48
|
Kulasegaram R, Richardson D, Macrae B, de Ruiter A. Mycobacterium xenopi osteomyelitis in a patient on highly active antiretroviral therapy (HAART). Int J STD AIDS 2016; 12:404-6. [PMID: 11368825 DOI: 10.1258/0956462011923219] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Skeletal infections with atypical mycobacteria are a manifestation of advanced HIV disease, most patients having CD4 counts of less than 100 cells/mm3. We report a case of Mycobacterium xenopi vertebral osteomyelitis in a patient on HAART with a CD4 count of 490 cells/mm3 and viral load below the level of detection at the time of diagnosis.
Collapse
Affiliation(s)
- R Kulasegaram
- Department of Genitourinary Medicine, St Thomas' Hospital, London SE1 7EH, UK
| | | | | | | |
Collapse
|
49
|
Abstract
We report an HIV-positive man who re-acquires hepatitis B with evidence of serological protection which then resolves while on anti-retrovirals including tenofovir.
Collapse
Affiliation(s)
- D Richardson
- Jefferiss Wing, St Mary's Hospital, London W2 1NY, UK
| | | |
Collapse
|
50
|
Bell C, Richardson D, Goldmeier D, Crowley T, Kocsis A, Hill S. Persistent sexual arousal in a woman with associated cardiac defects and raised atrial natriuretic peptide. Int J STD AIDS 2016; 18:130-1. [PMID: 17331290 DOI: 10.1258/095646207779949592] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The persistent sexual arousal syndrome (PSAS) is a newly described entity where the woman becomes involuntarily genitally aroused for extended periods of time in the absence of sexual desire and is distressed by this situation. The cause of this sexual problem is not well understood. We describe such a case where the subjective feelings were confirmed by observing genital engorgement. In her case, PSAS came on after initiation of fludrocortisone given for hypotension and bradycardia that was associated with an atrial septal defect (ASD). We argue that the combined effect of the ASD and fludrocortisone may be associated with an increase in her levels of atrial natriuretic peptide (ANP). ANP causes profound vasodilation and vascular leakage. We postulate that the high serum levels of ANP in her case may be contributory to her PSAS.
Collapse
Affiliation(s)
- C Bell
- The Jane Wadsworth Clinic, St Mary's Hospital, London, UK
| | | | | | | | | | | |
Collapse
|